Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on December 18, 2024. The report addresses a specific regulatory event regarding the company's listing status on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance event and does not contain financial performance data.
Material Changes
The primary material change reported is the restoration of compliance with Nasdaq Listing Rule 5550(a)(2). The company's common stock maintained a closing bid price of $1.00 per share or greater for 12 consecutive trading days between November 26, 2024, and December 12, 2024.
Guidance, Outlook, and Risks
The Nasdaq Listing Qualifications Staff issued a written notice of compliance, stating that the matter regarding the company's listing status is now considered closed. The filing does not contain forward-looking guidance, management commentary on operations, or disclosures of new risks or contingencies beyond the resolution of the listing deficiency.
Key Facts for Investor Verification
- The company regained compliance with Nasdaq minimum bid price requirements as of December 12, 2024.
- The Nasdaq Listing Qualifications Staff has officially closed the compliance matter.
- The stock traded at or above $1.00 per share for the required 12-day period.
- No financial results or operational updates are included in this specific filing.